Pulmonary hypertension due to left heart disease

Jean-Luc Vachiéry1, Ryan J. Tedford2, Stephan Rosenkranz3, Massimiliano Palazzini4, Irene Lang5, Marco Guazzi6, Gerry Coghlan7, Irina Chazova8 and Teresa De Marco9

Number 9 in the series
“Proceedings of the 6th World Symposium on Pulmonary Hypertension”
Edited by N. Galiè, V.V. McLaughlin, L.J. Rubin and G. Simonneau

Affiliations: 1Dept of Cardiology, Cliniques Universitaires de Bruxelles – Hôpital Erasme, Brussels, Belgium. 2Division of Cardiology, Dept of Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA. 3Clinic III for Internal Medicine, Dept of Cardiology, Heart Center at the University of Cologne and Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany. 4Dept of Investigational, Diagnostic and Specialty Medicine, Bologna, Italy. 5Dept of Cardiology, AKH-Vienna, Medical University of Vienna, Vienna, Austria. 6Dept of Biomedical Sciences for Health, University of Milan and Dept of Cardiology University, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. 7Dept of Cardiology, Royal Free Hospital, London, UK. 8Russian Cardiology Research Complex, Moscow, Russia. 9University of California, San Francisco, CA, USA.

Correspondence: Jean-Luc Vachiéry, Dept of Cardiology, Cliniques Universitaires de Bruxelles – Hôpital Erasme, 808 Route de Lennik, 1070 Brussels, Belgium. E-mail: jeanluc.vachiery@erasme.ulb.ac.be

@ERSpublications
State of the art and research perspectives in pulmonary hypertension due to left heart disease including diagnostic and treatment insights http://ow.ly/vr0I30md6KC


ABSTRACT Pulmonary hypertension (PH) is frequent in left heart disease (LHD), as a consequence of the underlying condition. Significant advances have occurred over the past 5 years since the 5th World Symposium on Pulmonary Hypertension in 2013, leading to a better understanding of PH-LHD, challenges and gaps in evidence. PH in heart failure with preserved ejection fraction represents the most complex situation, as it may be misdiagnosed with group 1 PH. Based on the latest evidence, we propose a new haemodynamic definition for PH due to LHD and a three-step pragmatic approach to differential diagnosis. This includes the identification of a specific “left heart” phenotype and a non-invasive probability of PH-LHD. Invasive confirmation of PH-LHD is based on the accurate measurement of pulmonary arterial wedge pressure and, in patients with high probability, provocative testing to clarify the diagnosis. Finally, recent clinical trials did not demonstrate a benefit in treating PH due to LHD with pulmonary arterial hypertension-approved therapies.
Introduction
Pulmonary hypertension (PH) is a common complication of left heart disease (LHD), in response to a passive increase in left-sided filling pressures, more specifically left atrial pressure [1]. It is currently defined as post-capillary PH, by an increase in mean pulmonary arterial pressure (mPAP) \( \geq 25 \text{ mmHg} \) and a pulmonary arterial wedge pressure (PAWP) \( >15 \text{ mmHg} \) [2]. In most cases, PH-LHD (group 2 PH) is a consequence or an abnormal biomarker of the underlying cardiac disorder. However, the structure and function of the pulmonary circulation may be further affected by several mechanisms potentially leading to pulmonary arterial and venous remodelling. In heart failure, recent data even suggest that the severity of PH correlates most strongly with venous and small arteriolar intimal thickening [1–3]. In addition, the function of the right ventricle is often affected independently from the afterload increase [4–7], leading to uncoupling of the right ventricle/pulmonary artery unit [8–10] with further exercise limitation and adverse outcome. This is especially true in heart failure with preserved ejection fraction (HFpEF) [4–11]. Over the past 5 years since the 5th World Symposium on Pulmonary Hypertension (WSPH) in 2013, significant advances have improved our understanding of PH-LHD. This article summarises these findings, key challenges and proposals for the approach to this condition, with a specific focus on PH due to HFpEF.

Definition and classification of PH-LHD
At the 5th WSPH in 2013, a new terminology was adopted to distinguish isolated post-capillary PH (IpcPH) from combined post-capillary and pre-capillary PH (CpcPH), based on the diastolic pressure difference/gradient (DPG) between the diastolic PAP (dPAP) and PAWP [1]. However, this definition was found to be too restrictive and exposed to interpretation, leading to controversies about whether the DPG would [12–15] or would not [16–21] predict outcome in patients with group 2 PH. Pulmonary vascular resistance (PVR) was subsequently reintroduced to better reflect the impact of the right ventricle on outcome [2]. To date, the haemodynamic definition of PH-LHD stands as: 1) post-capillary PH when mPAP \( \geq 25 \text{ mmHg} \) and PAWP \( >15 \text{ mmHg} \); 2) IpcPH when DPG \( <7 \text{ mmHg} \) and/or PVR \( \leq 3 \text{ Wood Units (WU)} \); and 3) CpcPH when DPG \( \geq 7 \text{ mmHg} \) and/or PVR \( >3 \text{ WU} \). These two distinct haemodynamic phenotypes may be further defined by several variables obtained during diagnostic right heart catheterisation (RHC), none being totally independent from potential limitations [22]. The combination of recent analyses and basic physiology reveals that the haemodynamic definition of PH-LHD relies heavily on the accurate measurement of PAWP.

What is a normal PAWP and how to measure it?
In normal individuals, PAWP is close to dPAP, with a mean±SD value of \( 8.0\pm2.9 \text{ mmHg} \) [23] for a normal What is a normal PAWP and how to measure it?
In normal individuals, PAWP is close to dPAP, with a mean±SD value of \( 8.0\pm2.9 \text{ mmHg} \) [23] for a normal...
Best practice suggests that RHC should be performed in stable, non-acute clinical conditions for the differential diagnosis of PH. Proper levelling at the mid-chest and “zero”ing the transducer to atmospheric pressure are critical. Patients should be positioned supine with legs flat and pressures recorded during spontaneous breathing (no breath-hold). Measurements should be repeated in triplicate to obtain values within a 10% agreement.

- If PAWP is elevated and the accuracy of PAWP is in question, blood oxygen saturation should be determined in the wedge position. If the PAWP oxygen saturation is <90%, direct LVEDP measurement should be obtained.
- The presence of significant, large v-waves should be noted as this strongly suggests LHD regardless of resting PAWP.

**How to define CpcPH?**

Evidence in PH-LHD has been generated since the 5th WSPH in 2013 to 1) characterise the clinical profile, 2) describe the haemodynamic features and 3) identify outcome predictors. Indeed, the presence and the identification of a pre-capillary component in post-capillary PH are critical as it may have an impact on prognosis, can modify management and serves as the basis for clinical trial design [32]. In addition, CpcPH is associated with a reduced exercise capacity and a phenotype similar to PAH [21, 33]. Finally, it has been recently suggested that CpcPH may present a genetic profile that could be different from IpcPH [16].

Nevertheless, the populations studied in these retrospective registries are heterogeneous, from pure heart failure with reduced ejection fraction (HFrEF) cohorts [16–18], all causes of LHD [12, 15, 20, 21, 28, 34], to pure valvular heart disease (VHD) registries [13, 14]. The typical profile of PH-LHD combines an elevated PAWP (>20 mmHg), a mildly elevated mPAP (25–40 mmHg), a low cardiac index (≤2.5 L·min⁻¹·m⁻²), an elevated transpulmonary pressure gradient (TPG) (>12 mmHg), a normal DPG (<3 mmHg) and PVR ranging from 3 to 4.9 WU. In addition, right atrial pressure is consistently elevated (>10 mmHg), which may, together with elevated PAWP, suggest fluid overload or pericardial constraint. Finally, most studies reported a significant proportion (roughly one-third) of negative DPG that may be explained by the aforementioned limitations [27]. This is in keeping with a high rate of atrial fibrillation, affecting around 40% of patients.

The search for an ideal predictor of outcome in PH-LHD has led to conflicting results. On multivariate analysis, several predictors were found: a combination of mPAP and PVR [13, 16], pulmonary arterial compliance (PAC) either alone [19, 20] or in combination with mPAP and PAWP [16], or a combination of mPAP and DPG [12]. A meta-analysis identified 10 retrospective analyses using PVR, DPG and/or PAC to predict survival in PH-LHD [35]. For the purpose of consistency, and to better individuate the risk associated with each variable, independently of arbitrary cut-offs, only studies reporting the prognostic power of continuous variables were included. The analysis was done on a total of 2513 patients, followed for up to 15 years. The haemodynamic profile revealed average values of mPAP, PVR, DPG and PAC of 35 mmHg, 3.0 WU, 1.2 mmHg and 2.5 mL·mmHg⁻¹, respectively. In this analysis, DPG, PVR and PAC appeared to be associated with survival. However, both PVR and PAC were stronger predictors of outcome when compared with DPG [35]. It was suggested that a combination of variables might be better than an isolated value for prognosis purposes [35]. Interestingly, a recent analysis of three large US cohorts showed that higher pulmonary artery elastance and lower PAC are associated with increased mortality and right ventricular dysfunction, across the spectrum of heart failure and even when resistive load was normal [36].

This strongly suggests that, in CpcPH due to heart failure, the total right ventricular load is closely linked to outcome. Finally, a recent large retrospective analysis of 2587 patients with PH-HFpEF showed that TPG ≥12 mmHg, PVR ≥3 WU and DPG ≥12 mmHg were predictors of mortality and heart failure hospitalisations [37].

Therefore, the best way to describe the pre-capillary component of post-capillary PH remains controversial; none of the haemodynamic variables proposed to describe PH-LHD [22] are free from limitations.

**Recommendations**

- After careful consideration of the changes in the general definition of PH [36], the proposed haemodynamic definition of PH in LHD is: 1) IpcPH: PAWP >15 mmHg and mPAP >20 mmHg and PVR <3 WU; and 2) CpcPH: PAWP >15 mmHg and mPAP >20 mmHg and PVR ≥3 WU.
- Beyond a strict haemodynamic definition, other markers of disease may be taken in consideration to better determine a patient’s prognosis. These could include an additional haemodynamic marker (e.g. DPG or PAC), cardiopulmonary exercise testing (CPET) profile (level of $V^\text{E}/V^\text{CO}_2$ (minute ventilation/oxygen uptake) slope, exercise oscillatory ventilation, end-tidal carbon dioxide tension
(PETCO₂), indices of right ventricular function and right ventricle/pulmonary artery coupling (compliance and elastance) and biomarkers. In the context of PH due to HFpEF, ST2, a member of the interleukin-1 superfamily, may be complementary to N-terminal pro-brain natriuretic peptide (NT-proBNP) [24].

- Given the limitations of pure haemodynamic definitions, future studies should be aimed at developing biomarkers and other non-haemodynamic diagnostics to discriminate IpcPH and CpcPH.

Diagnostic approach and differential diagnosis of PH-LHD

Although RHC is the gold standard for the diagnosis of PH, it is not sufficient to make a clear distinction between idiopathic PAH (IPAH) and PH-LHD, especially when risk factors or documented history of cardiovascular disease (CVD) coexist [1, 2, 32, 34, 38]. Therefore, we propose a three-step approach to the differential diagnosis: 1) identification of a clinical phenotype to establish the characteristics of group 2 PH, 2) determination of a pre-test probability to identify which patients should move to an invasive evaluation and 3) haemodynamic characterisation, which could include provocative testing in selected cases.

Clinical phenotype of PH due to LHD

The revised clinical classification distinguishes three main entities in group 2 PH [38]: 1) PH due to HFpEF, 2) PH due to HFrEF and 3) PH due to VHD. In contrast to the other aetiologies, the distinction between PH due to HFpEF, PAH and chronic thromboembolic PH (CTEPH) may be challenging. Indeed, traditional cardiovascular risk factors may be present in patients with PAH [32, 34, 39]. Patients with systemic sclerosis may present with left ventricular involvement, independent from the presence of PH and pulmonary vascular disease (PVD) [40]. In patients with CTEPH, PAWP may be difficult to measure due to pulmonary artery obstruction and LVEDP may be elevated as patients may have concomitant cardiac involvement [41]. Finally, patients with HFpEF [32] and PH due to HFrEF [42] may present with a low diffusing capacity of the lung for oxygen (DLCO), an independent predictor of outcome [43]. All these potential confounding factors may lead to misclassification of PH.

The latter may be avoided by combining factors that are typically associated with group 2 PH, which include clinical features, echocardiographic abnormalities and other tests (e.g. magnetic resonance imaging and CPET) [1, 2, 39]. Interestingly, the prevalence of such risk factors in the COMPERA registry is high, particularly in an older subgroup of patients with cardiovascular comorbidities (referred to as “atypical PAH”) and in patients with PH due to HFpEF [34]. Importantly, a high rate of atrial fibrillation was reported at the time of diagnosis in IPAH, “atypical PAH” and PH due to HFpEF, in 10%, 42% and 54%, respectively.

Pre-test probability of PH due to LHD

As a single variable will unlikely be sufficient for accurate differential diagnosis, a combination of the previous features may help to determine a pre-test probability of group 2 PH. Composite scores integrating clinical and non-clinical features were derived from retrospective single-centre analyses [44–48], lacking external validation. A proposal to integrate these features is shown in table 1, some being markers of high probability of PH-LHD (previous cardiac interventions, presence of atrial fibrillation at diagnosis, evidence for structural LHD and CPET abnormalities). This approach is in line with the current strategy for the general diagnosis of PH [2, 49] and has also recently been suggested in the assessment of HFpEF [50].

Haemodynamic evaluation of PH-LHD

As a general rule, the decision for invasive confirmation of PH-LHD assumes the presence of an intermediate to high probability of PH based on symptoms and echocardiographic features, following the revised diagnostic algorithm [51]. In patients with a high probability of LHD as a cause of PH, the general management should be guided according to the recommendation for the underlying condition. In patients with an intermediate probability, invasive characterisation may be performed in patients with risk factors for PAH (e.g. systemic sclerosis), CTEPH or in cases of unexplained dyspnoea. The presence of right ventricular abnormalities also requires invasive assessment as it may have an influence on management (figure 1a). Due to the presence of multiple confounding factors and the complexity of the interpretation of invasive measurements, RHC should be performed in expert centres [2]. Provocative testing during RHC may be useful in the distinction between healthy subjects and HFpEF [51–54] or to uncover PH-LHD in patients with PAWP at the upper limit of normal (ULN) (i.e. 13–15 mmHg) [55–58]. For this purpose, both exercise testing and fluid loading are used in clinical practice (table 2).

The ULN of mPAP during an incremental dynamic exercise challenge has been suggested at >30 mmHg with a cardiac output (CO) <10 L·min⁻¹, which corresponds to a total pulmonary vascular resistance (TPR=mPAP/CO) of 3 WU [59, 60]. The ULN of PAWP during exercise is thought to be between 15 and
In elderly subjects, PAWP values can be higher but not necessarily abnormal [59, 60]. Other factors such as body position (supine versus upright), age, sex, and timing over the respiratory cycle [60, 61–64] may influence PAWP during exercise. Body position can affect PAWP by approximately 5 mmHg, with values being higher in the supine position. Age, sex, duration of exercise, and timing over the respiratory cycle also impact PAWP measurement.

Recent data suggest that initial increases in PAWP and mPAP in middle-aged healthy individuals do not necessarily reflect abnormal cardiopulmonary physiology [61]. Pressures may normalize within minutes [61]. The ULN to detect an abnormal response of PAWP to exercise is unknown. Some authors suggest a cut-off value of 25 mmHg for the diagnosis of heart failure [51–54], although PAWP >25 mmHg has been found in elderly individuals free of apparent CVD [61]. Different cut-offs may be used according to age and sex [55, 62, 63]. Therefore, a flow-adjusted measure of PAWP may be more appropriate than PAWP alone [59, 60], with recent work suggesting a PAWP/CO slope >2 mmHg·L⁻¹·min⁻¹ is associated with reduced functional capacity, higher NT-proBNP and reduced heart failure-free survival [61].

As measurements of pressures during exercise are technically difficult and require specialised equipment, a fluid challenge may be easier to standardise and more readily available. Any condition associated with reduced left ventricular diastolic compliance or VHD will be associated with a rapid increase in PAWP when challenged with an increased systemic venous return [53, 54]. Although not as profound, fluid loading also increases PAWP in healthy volunteers as a function of age, sex, amount infused and infusion rate [52]. Thus, the standardisation of the test cut-off values for PAWP requires aflow-adjusted measure of PAWP to be more than just PAWP alone [59, 61], with recent work suggesting a PAWP/CO slope >2 mmHg·L⁻¹·min⁻¹ is associated with reduced functional capacity, higher NT-proBNP and reduced heart failure-free survival [61].

Table 1. Pre-test probability of left heart disease (LHD) phenotype

<table>
<thead>
<tr>
<th>Feature</th>
<th>High probability</th>
<th>Intermediate probability</th>
<th>Low probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>&gt;70 years</td>
<td>60–70 years</td>
<td>&lt;60 years</td>
</tr>
<tr>
<td>Obesity, systemic hypertension, dyslipidaemia, glucose intolerance/diabetes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Previous cardiac intervention#</td>
<td>Current</td>
<td>Paroxysmal</td>
<td>Normal or signs of RV strain</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>Present</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Structural LHD</td>
<td>LA dilation; grade &gt;2 mitral flow</td>
<td>No LA dilation; grade &lt;2 mitral flow</td>
<td>No LA dilation; E/e' &lt;13</td>
</tr>
<tr>
<td>ECG</td>
<td>LBBB or LVH</td>
<td>Mild LVH</td>
<td>No</td>
</tr>
<tr>
<td>Echocardiography</td>
<td>Mildly elevated V'/V'CO₂ slope; EOV</td>
<td>Elevated V'/V'CO₂ slope or EOV</td>
<td>No EOV</td>
</tr>
<tr>
<td>CPET</td>
<td>LA strain or LA/RA &gt;1</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Cardiac MRI</td>
<td></td>
<td></td>
<td>Normal or signs of RV strain</td>
</tr>
</tbody>
</table>

LBBB: left bundle branch block; LVH: left ventricular hypertrophy; RV: right ventricular; LA: left atrial; E/e': early mitral inflow velocity/mitral annular early diastolic velocity ratio; CPET: cardiopulmonary exercise testing; V̇E: minute ventilation; V'CO₂: carbon dioxide production; EOV: exercise oscillatory ventilation; MRI: magnetic resonance imaging; RA: right atrial. #: coronary artery and/or valvular surgical and/or non-surgical procedures, including percutaneous interventions.

Recommendations

- The nomenclature of “PAH with cardiovascular risk factors” should be preferred over any other, to account for their coexistence without suggesting that risk factors may be influencing the cause of the PVD. The role of comorbidities in the disease process of PAH is not demonstrated and remains unclear.
- A three-step approach should be followed to perform the differential diagnosis between group 2 PH (mainly HFrEF) and PAH: 1) identification of a clinical phenotype suggesting PH-LHD, 2) determination of a pre-test probability for PH-LHD and 3) haemodynamic characterisation.
- Invasive assessment should be performed in patients with intermediate probability of PH-LHD, presence of right ventricular abnormality and when risk factors for PAH/CTEPH coexist (figure 1b).
- In patients with a PAWP 13–15 mmHg and high/intermediate probability of PH-HFpEF, provocative testing should be considered to uncover PH due to HFpEF. For technical reasons and reliability of pressure recording, a fluid challenge is preferred over exercise in the approach to differential diagnosis.
- PAWP >18 mmHg immediately after administration of 500 mL of saline over 5 min is considered abnormal.

https://doi.org/10.1183/13993003.01897-2018
However, how this should impact management is unknown. If PAH-specific therapies are initiated in patients with an "abnormal" response, caution should be exercised, including close monitoring of response and side-effects.

Clinical trials and therapy for PH due to LHD

Pathways involved in the development of PAH may contribute to the pathogenesis of heart failure and PH due to LHD, providing a rationale for investigating the role of their modulation in this setting [1, 2, 32, 39]. Until recently, most studies were performed in HFrEF patients, leading to disappointing results [1, 2, 32, 39]. The results of the ENABLE trials with bosentan were recently published, confirming that blocking endothelin-1 has no effect on outcome in patients with HFrEF [67]. The SOCRATES programme assessed the role of vericiguat, a guanylate cyclase stimulator, in HFrEF [68] and HfPES [69]. In SOCRATES-Reduced, vericiguat did not change the NT-proBNP level at 12 weeks compared with placebo [68]. Similar results were observed in SOCRATES-Preserved, with no effect on left atrial volume index, the coprimary end-point [69]. Inhaled sodium nitrite has been shown to acutely decrease left-sided filling pressures and PAP at rest [70] and exercise [71]. However, the multicentre INDIE-HFpEF trial (ClinicalTrials.gov identifier NCT02742129) did not show a benefit of the compound on exercise capacity in HFpEF after 12 weeks [72]. Since 2013, several randomised controlled trials have been completed in patients with PH-LHD (table 4). The effects of 60 mg sildenafil 3 times a day were compared with placebo in 52 patients with PH due to HFpEF at 12 weeks [73]. No effect was observed on the primary end-point of mPAP, while a decrease in PVR and an improvement in exercise capacity were previously shown in a single-centre trial [74]. Riociguat, a guanylate cyclase stimulator, did not improve mPAP after 12 weeks in patients with PH due to HFrEF [75].
TABLE 2 Pulmonary arterial wedge pressure (PAWP) response to exercise in normal and heart failure with preserved ejection fraction (HFpEF), and response to fluid loading in normal, HFpEF and pulmonary hypertension (PH)

<table>
<thead>
<tr>
<th>First author [ref.]</th>
<th>Subjects n</th>
<th>Age (sex)</th>
<th>Protocol</th>
<th>Average PAWP: rest to peak mmHg</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exercise</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WRIGHT [62]</td>
<td>28 healthy</td>
<td>55 years (12 female)</td>
<td>Semi-upright</td>
<td>11±3–22±5 early to 17±6 late</td>
<td>Time-variant changes, early increase and late decrease</td>
</tr>
<tr>
<td>WOLSK [63]</td>
<td>62 healthy</td>
<td>20–80 years (50% female)</td>
<td>Supine</td>
<td>8–10 rest; 16 leg raising; 19 at 25% peak $\dot{V}O_2$; 23 at 75% peak $\dot{V}O_2$</td>
<td>35% elderly had PAWP $&gt;25$ mmHg</td>
</tr>
<tr>
<td>ANDERSEN [52]</td>
<td>26 (14 HFpEF, 12 controls)</td>
<td>70 years HFpEF (57% female); 63 years controls (58% female)</td>
<td>Supine exercise versus fluid loading</td>
<td>Control: 7±3–13±5; HFpEF: 14±3–32±6</td>
<td>Similar increase in healthy subjects; 2-fold increase in all filling pressures during exercise versus fluid loading in HFpEF</td>
</tr>
<tr>
<td><strong>Fluid loading</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FUJIMOTO [53]</td>
<td>60 healthy; 11 HFpEF</td>
<td>Young: &lt;50 years; older: $\geq$50 years</td>
<td>100–200 mL·min$^{-1}$</td>
<td>Young: 10±2–16±2; older: 9±2–17±2; HFpEF: 14±4–20±4</td>
<td>Normals reach PAWP 18–19 mmHg</td>
</tr>
<tr>
<td>ANDERSEN [52]</td>
<td>26 (14 HFpEF, 12 controls)</td>
<td>70 years HFpEF (57% female); 63 years controls (58% female)</td>
<td>10 mL·kg$^{-1}$·min$^{-1}$ saline (150 mL·min$^{-1}$)</td>
<td>Control: 7±3–13±5; HFpEF: 14±3–21±4</td>
<td>Similar increase of PAWP in healthy subjects</td>
</tr>
<tr>
<td>FOX [55]</td>
<td>107 SSc with PH suspicion</td>
<td>59 years PAH (94% female); 66 years OPVH (64% female)</td>
<td>500 mL saline (5–10 min)</td>
<td>PAH: 8±3–12±2 (LVEDP 9–12); OPVH: 12±3–17±5 (LVEDP 15–21)</td>
<td>Retrospective analysis; OPVH defined by increase in PAWP $&gt;15$ mmHg</td>
</tr>
<tr>
<td>ROBBINS [57]</td>
<td>207 PAH</td>
<td>51 years PAH (82% female); 57 years OPVH (74% female)</td>
<td>500 mL saline (5–10 min)</td>
<td>PAH: 9±3–11±4; OPVH: 12±2–19±3</td>
<td>Retrospective analysis; 30% had increase in PAWP $&gt;15$ mmHg, predominantly female, mostly in normal range</td>
</tr>
<tr>
<td>D’ALTO [65]</td>
<td>212 PH evaluation</td>
<td>58 years pre-capillary (68% female); 65 years post-capillary</td>
<td>7 mL·kg$^{-1}$ rapid infusion</td>
<td>PAH: 9±2–12±2; HPH: 11±2–22±3</td>
<td>Overlap between groups; cut-off for PAWP abnormal response at 18 mmHg</td>
</tr>
</tbody>
</table>

$\dot{V}O_2$: oxygen uptake; SSc: systemic sclerosis; PAH: pulmonary arterial hypertension; LVEDP: left ventricular end-diastolic pressure; OPVH: occult pulmonary venous hypertension (defined as PAWP $>15$ mmHg after fluid loading); HPH: hidden pulmonary hypertension due to left heart disease.

The MELODY-1 study was the only study specifically including patients with CpcPH [76]. Patients were randomised to placebo or macitentan 10 mg. The main end-point assessed a composite of significant fluid retention (weight gain $\geq$5% or $\geq$5 kg because of fluid overload or parenteral diuretic administration) or worsening in New York Heart Association Functional Class (NYHA FC) from baseline to end of treatment. Exploratory end-points included changes in NT-proBNP and haemodynamics at week 12. Treatment with macitentan was associated with a 10.1% increased risk of fluid retention in normal range.

The SIOVAC trial aimed to determine whether treatment with sildenafil improves outcomes of patients with persistent PH after correction of VHD [77]. Patients who had undergone a successful valve replacement or repair procedure at least 1 year before inclusion were randomised to 40 mg sildenafil 3 times daily (n=104) versus placebo (n=96) for 6 months. The primary end-point was a composite clinical score combining death, hospital admission for heart failure, change in NYHA FC and patiend global self-assessment. Improvement in the clinical score was significantly more frequent in the placebo group (44 versus 27 patients receiving sildenafil). In contrast, worsening was more common in the sildenafil group (33 versus 14 patients in the placebo group). The Kaplan–Meier estimates for survival without admission due to heart failure were 0.76 and 0.86 in the sildenafil and placebo group, respectively, although this did not reach statistical significance.

The typical profile of patients included in the trials modulating the nitric oxide/cGMP pathway shows an elderly (70 years) female predominance, with a high rate of atrial fibrillation at baseline (44–77%) and...
preserved ejection fraction in more than half of the cases. With the exception of the MELODY trial, patients had IpcPH, as shown by a combination of DPG around 2 mmHg and PVR below or slightly above 3 WU [73, 75, 77]. In contrast, the patients recruited in the MELODY trial had a typical CpcPH profile, which was associated with higher baseline NT-proBNP, reflecting worse right ventricular function [76]. Several studies using PAH therapies/pathways in PH-LHD are underway (table 5).

### PH and vasoreactivity testing in end-stage heart failure

In the context of heart transplantation, PH is associated with an increased 30-day mortality in patients with TPG >15 mmHg and PVR >5 WU [78]. A continuous risk of morbidity and mortality increases with progressive elevation in mPAP, TPG and PVR [79]. Finally, PH reverses soon after heart transplantation, the most pronounced reduction in PVR occurring within 1 month post-transplant [80]. Implantation of a left ventricular assist device (LVAD) rapidly reduces “fixed” PH in heart transplant candidates, with survival outcomes comparable to patients without [81]. In addition, right ventricular afterload almost always declines with LVAD insertion and does so rapidly [82]. It is therefore recommended to perform RHC in all candidates before listing and at 3–6-month intervals in listed patients, especially in the presence of reversible PH or worsening heart failure [83]. LVAD recipients with at least one post-implant RHC without PH likely require less frequent assessments [84]. The current recommendations for heart transplantation suggest that an acute vasodilator challenge should be performed if sPAP >50 mmHg, and either TPG \( \geq 15 \text{ mmHg} \) or PVR >3 WU and systemic systolic arterial pressure >85 mmHg [83]. However,

### TABLE 3 Limitations and advantages of exercise testing and fluid loading in the assessment of pulmonary hypertension

<table>
<thead>
<tr>
<th></th>
<th>Exercise testing</th>
<th>Fluid loading</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical relevance for</strong></td>
<td>+ + +</td>
<td>+</td>
</tr>
<tr>
<td><strong>symptom assessment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical relevance for</strong></td>
<td>+</td>
<td>+ + +</td>
</tr>
<tr>
<td><strong>differential diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Main advantages</strong></td>
<td>Respects the pathophysiology; comprehensive test, allowing for additional insights in pulmonary vascular disease (dynamic pulmonary vascular resistance); complementary with cardiopulmonary exercise testing</td>
<td>Easy to perform, no specific setting; minimal risk of misinterpretation of pressures reading; better established cut-off defining abnormal increase in pulmonary arterial wedge pressure</td>
</tr>
<tr>
<td><strong>Main limitations</strong></td>
<td>Requires a specific complex setting; expertise in conducting the test; pressure reading during exercise; range of normal response uncertain</td>
<td>Unknown response in disease state; age dependency of response</td>
</tr>
<tr>
<td><strong>Standardised protocol</strong></td>
<td>+/-</td>
<td>++</td>
</tr>
</tbody>
</table>

### TABLE 4 Recently completed randomised controlled trials targeting the phosphodiesterase type 5 inhibitor/nitric oxide and endothelin pathways in pulmonary hypertension due to left heart disease

<table>
<thead>
<tr>
<th>First author or study [ref.]</th>
<th>Study drug</th>
<th>Dose</th>
<th>Subjects</th>
<th>Duration</th>
<th>Population</th>
<th>Primary outcome</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GUazzi [74]</strong></td>
<td>Sildenafil</td>
<td>50 mg 3 times a day</td>
<td>44</td>
<td>12 months</td>
<td>HFpEF</td>
<td>PVR, RV performance, CPET</td>
<td>Improvement</td>
</tr>
<tr>
<td><strong>LEPHT [75]</strong></td>
<td>Riociguat</td>
<td>0.5, 1 or 2 mg 3 times a day</td>
<td>201</td>
<td>16 weeks</td>
<td>HFrEF</td>
<td>mPAP versus placebo</td>
<td>No change</td>
</tr>
<tr>
<td><strong>HOENDERMIS [73]</strong></td>
<td>Sildenafil</td>
<td>60 mg 3 times a day</td>
<td>52</td>
<td>12 weeks</td>
<td>HFpEF</td>
<td>mPAP versus placebo</td>
<td>No change</td>
</tr>
<tr>
<td><strong>SIOVAC [77]</strong></td>
<td>Sildenafil</td>
<td>40 mg 3 times a day</td>
<td>231</td>
<td>24 weeks</td>
<td>VHD</td>
<td>Composite clinical score⁶</td>
<td>Worsening in active group</td>
</tr>
<tr>
<td><strong>MELODY-1 [76]</strong></td>
<td>Macitentan</td>
<td>10 mg once daily</td>
<td>48</td>
<td>12 weeks</td>
<td>HF (EF &gt;30%); 75% HFpEF</td>
<td>Safety and tolerability</td>
<td>+10% fluid retention in active group</td>
</tr>
</tbody>
</table>

there is no specific recommendation on the agent to be used. Outside of this setting, the role of vasoreactivity testing does not clearly predict outcome in PH-LHD [1, 2, 20]. Finally, there is a paucity of evidence supporting the use of PAH-approved therapies in patients awaiting heart transplantation and/or LVAD.

**Recommendations**

- There is still no multicentre trial that suggests targeting PH-LHD with PAH-specific drugs is beneficial. Therefore, we maintain a strong recommendation against the use of PAH therapies in group 2 PH.
- In addition, a safety signal should be acknowledged: 1) the use of sildenafil in the context of PH post-VHD intervention is associated with an increased risk of clinical deterioration and death, and 2) the use of macitentan in CpcPH due to heart failure is associated with an increased risk of fluid retention.
- Following the MELODY-1 trial, new standards have been proposed to explore the role of PAH-approved therapies in the context of group 2 PH. If pursued, such trials should be limited to PH due to HFP EF with CpcPH. The agent of choice should ideally be a HFP EF disease-modifying drug. Finally, a proof-of-concept study should be performed first, with safety and tolerability, haemodynamic and/or CPET efficacy end-points.
- Vasoreactivity testing is not recommended in patients with PH-LHD, outside of the context of assessment for heart transplantation.

**Conclusions**

PH is common in LHD; it is not a disease, although a subset of patients present with significant pulmonary vascular changes. Clinical research and prospective long-term multicentre analysis of PH-HFP EF cohorts may help to better identify risk factors for CpcPH and provide insights on outcome predictors. A pre-test probability assessment of LHD should be part of the diagnostic approach of PH. Further studies are needed to develop a multidimensional prediction score. Invasive confirmation on RHC requires attention to accurate resting PAWP measurement, at end-diastole and end-expiration. An increase of PAWP >18 mmHg after fluid loading, in patients with resting values between 13 and 15 mmHg and

---

**TABLE 5** Planned and ongoing trials in pulmonary hypertension (PH) due to left heart disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Study drug</th>
<th>Dose</th>
<th>Subjects</th>
<th>Duration</th>
<th>Population</th>
<th>Primary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>SERENADE (NCT03153111)</td>
<td>Macitentan</td>
<td>10 mg once daily</td>
<td>300</td>
<td>52 weeks</td>
<td>LVEF &gt;40% and ESC-defined HFpEF; HF hospitalisation within 12 months and/or PAWP or LVEDP &gt;15 mmHg within 6 months; elevated NT-proBNP; PVD or RVD</td>
<td>% change from baseline in NT-proBNP at week 24</td>
</tr>
<tr>
<td>SOPRANO (NCT02554903)</td>
<td>Macitentan</td>
<td>10 mg once daily</td>
<td>78</td>
<td>12 weeks</td>
<td>LVAD within 45 days; PH by RHC with PAWP ≤18 mmHg and PVR &gt;3 WU</td>
<td>PVR ratio of week 12 to baseline</td>
</tr>
<tr>
<td>DYNAMIC (NCT02744339)</td>
<td>Oral riociguat</td>
<td>1.5 mg 3 times a day</td>
<td>114</td>
<td>26 weeks</td>
<td>HFpEF; mPAP &gt;25 mmHg and PAWP &gt;15 mmHg</td>
<td>Change in CO</td>
</tr>
<tr>
<td>Oral treprostinil (NCT03037580)</td>
<td>Oral treprostinil</td>
<td></td>
<td>310</td>
<td>24 weeks</td>
<td>LVEF ≥50%; RHC within 90 days of randomisation; 6MWD &gt;200 m</td>
<td>Change in 6MWD from baseline to week 24</td>
</tr>
<tr>
<td>PASSION (not registered)</td>
<td>Oral tadalafil</td>
<td>40 mg once daily</td>
<td>320</td>
<td>NA</td>
<td>HFpEF; PH with PAWP &gt;15 mmHg and mPAP &gt;25 mmHg and PVR &gt;3 WU</td>
<td>Time to first event defined as HF-associated hospitalisation (independently adjudicated) or death from any cause</td>
</tr>
</tbody>
</table>

#: ClinicalTrials.gov identifier numbers are provided where possible. LVEF: left ventricular ejection fraction; ESC: European Society of Cardiology; HF: heart failure; pEF: preserved ejection fraction; PAWP: pulmonary arterial wedge pressure; LVEDP: left ventricular end-diastolic pressure; NT-proBNP: N-terminal pro-brain natriuretic peptide; PVD: pulmonary vascular disease; RVD: right ventricular dysfunction; LVAD: left ventricular assist device; RHC: right heart catheterisation; PVR: pulmonary vascular resistance; mPAP: mean pulmonary arterial pressure; CO: cardiac output; 6MWD: 6-min walk distance; NA: not available.

---

https://doi.org/10.1183/13993003.01897-2018
intermediate/high probability of HFpEF, may be considered abnormal. However, we strongly encourage further study of this population as well as non-haemodynamic, alternative strategies to differentiate IpcPH and CpcPH. The CpcPH haemodynamic presentation is now defined by PVR >3 WU on top of a post-capillary PH phenotype. Finally, multicentre randomised trials using PAH therapies in PH-LHD have not demonstrated benefit and have raised safety concerns. Their use is still not recommended in PH-LHD.

Conflict of interest: J-L. Vachiéry reports consultancy and speaker fees paid to institution, and is an investigator in clinical trials for Actelion Pharmaceuticals and Bayer, consultancy fees paid to institution from Novartis, and consultancy fees paid to institution, and is an investigator in clinical trials for Sonivie and Pfizer, during the conduct of the study; consultancy fees paid to institution, and is an investigator in clinical trials for Arena Pharmaceuticals, Bial Portela and Sonivie, consultancy and speaker fees paid to institution, and is an investigator in clinical trials for GSK and Pfizer, consultancy fees and travel grants paid to institution from MSD, and is an investigator in clinical trials for Reata, outside the submitted work. R.J. Tedford reports personal fees (Hemodynamic Core Lab) from Actelion, J&J and Merck, and personal fees for steering committee membership from Abbott, outside the submitted work. S. Rosenkranz reports personal fees for lectures and/or consultancy from Abbott, Actelion, Arena, Bayer, BMS, MSD, Novartis, Pfizer and United Therapeutics, and institutional research grants from Actelion, Bayer, Novartis, Pfizer and United Therapeutics, outside the submitted work; and serves as chair of the Working Group "Pulmonary circulation and right ventricular function" of the European Society of Cardiology. M. Palazzini has nothing to disclose. I. Lang reports grants and personal fees from Actelion and AOP Orphan Pharma, and personal fees from Sanofi and Novartis, outside the submitted work. M. Guazzi has nothing to disclose. G. Coghlan has nothing to disclose. I. Chazova has nothing to disclose. T. De Marco reports grants from Actelion Pharmaceuticals, Pfizer, United Therapeutics, Gilead, Boston Scientific, Bellerophon, Respirex, Arena Pharmaceutical and Novartis, outside the submitted work.

References


Inhaled sodium nitrite improves rest and exercise hemodynamics in heart

dysfunction.

Borlaug BA, Koepp KE, Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular

dysfunction.

et al.

Inorganic nitrite delivery to improve exercise capacity in heart failure patients with preserved ejection fraction: a randomized controlled


